Survey data for Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon

This dataset consists of a single, openly-accessible OpenDocument Spreadsheet (<b>.ods</b>) file containing aggregated survey data on new cases of tuberculosis and Rifampicin resistance in Cameroon. Survey data were collected from all 248 tuberculosis (TB) diagnostic and treatment centres (DTC) managed by the National TB Programme (NTP), over a period of 6 weeks: 13th of March to 21st of April 2017.<br>Camerooon's network of DTCs diagnose virtually all of the country's TB cases. The related study investigated a 'notification gap' between the 175 actual Rifampicin resistant and/or multidrug resistant (RR/MDR-TB) patients and the WHO-estimated figure of 1,200 RR/MDR-TB cases. The study addresses whether this gap can be accounted for by testing new bacteriologically confirmed pulmonary TB cases (PTB+ NC).<br>All patients aged 15 years and above presenting at each DTC with symptoms compatible with pulmonary TB were asked according to NTCP guidelines to submit two sputum samples which were examined microscopically. A patient with a positive sputum for acid-fast bacilli (AFB) who had never been treated with anti-tuberculosis drugs for more than one month was considered a new pulmonary TB case with bacteriological confirmation (PTB+NC). Patients previously treated for TB as well as those with uncertain TB antecedents were excluded from the study.<br><br>The dataset contains data on the following variables for the 10 regions of Cameroon and the country in total:<br><b>Reg: </b>Region<b>Pop: </b>Population<b>NC: </b>New cases of PTB reported in this study<b>RR:</b> New cases of Rifampicin resistant PTB reported in this study<b>in_NC:</b> Incidence rate of new cases of PTB per 100,000 of overall population<br><b>in_RR:</b> Incidence rate of new cases of PTB with Rifampicin resistance per 100,000 of overall population<b>Sample: </b>Number of NC cases with positive Rifampicin resistance sample result<br><b>Prop_RR:</b> Proportion of new cases of PTB reported with Rifampicin resistance in this study<br><b>Conf_1 and </b><b>Conf_2: </b>Confidence intervals for estimated prevalence of MDR-TB in new bacteriologically-confirmed pulmonary TB cases<b>RR_2016</b><b>:</b> Rifampicin resistant and/or multidrug resistant (RR/MDR-TB) cases actually reported by DTCs in 2016<br><b>In_RR_2016: </b>Incidence rate of RR/MDR-TB per 100,000 of overall population as reported by DTCs in 2016<br><b>inTPM+-NC 2016: </b>Incidence rate of new cases of Rifampicin resistant PTB per 100,000 of overall population as reported by DTCs in 2016<br>The 10 regions of Cameroon are outlined in the related publication.